Aromasin exemestane: Phase II data; Phase III; marketed as second-line therapy

In a Phase II study of patients with advanced estrogen-dependent breast cancer, Aromasin reduced the size of breast tumors in 11 of 12 evaluable patients when given prior to surgery, with an 85.5 perc...